Seoul Techno Holdings has invested an undisclosed amount in MVRIX, a next-generation in-vivo cancer therapy developer that manufactures therapeutic agents directly inside the patient’s body.

MVRIX is a biotech specialist founded by professors from Seoul National University and Sungkyunkwan University, R&D and manufacturing experts from global pharmaceutical companies, and executives with startup and financial sector experience. Sangwon Jung serves as CEO.
The company’s core competitive advantage is its proprietary Navibody platform technology, which delivers therapeutic substances precisely to target cells. Conventional cell therapies such as CAR-T require extracting cells from a patient’s blood, engineering them outside the body, and re-infusing them—a process that incurs high costs and long production timelines. MVRIX’s approach, delivered via a simple injection, converts immune cells directly into therapeutic cells inside the body, dramatically simplifying the production process and offering strong scalability across multiple disease indications.
MVRIX’s lead drug candidate, MIC-001, recently demonstrated excellent in-vivo functionality in preclinical validation, showing precise delivery to target T cells and effective depletion of target B cells. Building on these results, the company plans to accelerate development for autoimmune diseases and blood cancers while expanding the Navibody platform to address a broader range of conditions including solid tumors.
“MVRIX has secured differentiated LNP-based targeted delivery technology and production efficiency in the in-vivo CAR-T space where global big pharma are concentrating their efforts,” said Inhwan Cha, CEO of Seoul Techno Holdings. “We expect the company to maximize its platform competitiveness, which can extend beyond a single drug to diverse disease areas.”
Sangwon Jung, CEO of MVRIX, said, “With this investment, we will enhance the completeness of our pipeline and focus on preparing for full-scale clinical trials. We will accelerate global licensing deals and clinical entry based on our proven technology platform.”
MORE FROM THE POST
- MVRIX Raises $6.1M Series B to Advance In Vivo CAR-T Development with Antibody-Guided mRNA Platform
- Marrow Therapeutics Launches With $173M Series A and B for Bone Marrow-Targeted Genetic Medicines
- Biomolecular AI Startup Boltz Raises $110M Series A Led by Bessemer
- AI Drug Design Lab Isomorphic Labs Raises $5B Series C
- Anti-Aging RNA Therapeutics Developer Lifeplex Science Raises USD 5.3M Series A
Share
Most Read
- 1
- 2
- 3
- 4
- 5


Leave a Reply